UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. ガンシクロビルおよびバルガンシクロビル：概要ganciclovir and valganciclovir an overview [show details]
…maintenance; Dose modification of IV ganciclovir in patients with renal dysfunction is reviewed separately. See Ganciclovir (systemic): Drug information, section Dosing: Renal Impairment. The dosing of intraocular …
2. 成人の肝硬変患者に対する薬剤調整の概要overview of medication adjustments for adult patients with cirrhosis [show details]
… but without an indication for long-term use . Data on drug dose modification for patients with cirrhosis are limited, although empiric dose reduction combined with clinical monitoring (eg, liver biochemical …
3. 腎障害患者に生じる抗がん剤の腎毒性と用量調整：既存の細胞障害性抗がん剤chemotherapy nephrotoxicity and dose modification in patients with kidney impairment conventional cytotoxic agents [show details]
… recommends a 25 percent dose reduction in IV melphalan for CrCl 10 to 50 mL/min and a 50 percent dose reduction for CrCl <10 mL/min . Aronoff recommends the following dose modification for oral melphalan : …
4. 腎不全患者に生じる抗がん剤の腎毒性と用量変更：分子標的薬および免疫療法chemotherapy nephrotoxicity and dose modification in patients with kidney impairment molecularly targeted agents and immunotherapies [show details]
…biologic agents, preventive strategies, and recommended dose modifications in patients with kidney impairment. Nephrotoxicity and renal dose modification for conventional chemotherapeutic drugs, immune-mediated …
5. 肝疾患を有する患者における化学療法による肝毒性および用量調整：分子標的薬chemotherapy hepatotoxicity and dose modification in patients with liver disease molecularly targeted agents [show details]
…recommendations for dose modification in the event of persistent grade 2 or more severe hepatotoxicity. Encorafenib is primarily metabolized by the liver. There are no recommended dose modifications for preexisting …